| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg | |||
| Other Sizes |
| Targets |
Bruton's tyrosine kinase (BTK); irreversibly inhibits BTK by covalent binding to cysteine 481 in the kinase domain.
|
|---|---|
| ln Vitro |
BTK inhibitor 10 shows potent inhibition of BTK kinase activity in cell-free assays. It demonstrates significant efficacy in cellular models of B-cell receptor signaling, inhibiting BTK autophosphorylation and downstream signaling pathways. The compound shows selectivity for BTK over other kinases, though specific IC50 values are not extensively reported.
|
| ln Vivo |
In CIA mice, BTK inhibitor 10 (oral gavage; 30 mg/kg; once daily; 21 days) markedly reduced arthritic symptoms. Each of the mouse's four paws received a score ranging from 0 to 4, and the overall score for the limb was determined. In contrast to a control group score of 8.33, BTK030 decreased arthritis scores to 3.62 after 21 days of oral therapy [1].
In collagen-induced arthritis (CIA) mice, BTK inhibitor 10 (30 mg/kg, oral gavage, once daily for 21 days) significantly improves arthritis symptoms, including reduced paw swelling, decreased clinical scores, and reduced joint inflammation. The compound shows oral bioavailability and efficacy in autoimmune disease models. |
| Enzyme Assay |
BTK kinase assay: Recombinant human BTK (5 nM) is incubated with a peptide substrate (e.g., biotinylated BTK substrate peptide, 1 uM) and ATP (10 uM) in 50 mM HEPES pH 7.5, 10 mM MgCl2, 1 mM DTT for 30 minutes at 30degC. Phosphorylation is measured by AlphaScreen or ELISA using anti-phosphotyrosine antibody. IC50 is calculated from dose-response curves with BTK inhibitor 10 (0.01-1000 nM).
|
| Cell Assay |
B-cell receptor signaling assay: Ramos or Raji B cells are treated with BTK inhibitor 10 (0.1-1000 nM) for 2 hours, then stimulated with anti-IgM (10 ug/mL) for 5-10 minutes. Cells are lysed, and BTK phosphorylation at Y223 and downstream signaling (PLCgamma2, ERK) are analyzed by Western blot. IC50 for inhibition of BTK phosphorylation is calculated.
|
| Animal Protocol |
Animal/Disease Models: DBA/1J mice injected with collagen as CIA model [1]
Doses: 30 mg/kg Route of Administration: po (oral gavage); 21 days; one time/day Experimental Results: Compared with the control group, arthritis scores were Dramatically higher reduce. Collagen-induced arthritis (CIA) mouse model: DBA/1J mice are immunized with bovine type II collagen in CFA on day 0 and boosted on day 21. When arthritis develops (day 25-30), mice are treated with BTK inhibitor 10 (30 mg/kg, p.o., once daily) for 21 days. Clinical scores are recorded every 2-3 days, and paw swelling is measured by caliper. Joints are harvested for histology at endpoint. |
| ADME/Pharmacokinetics |
Mouse PK following oral administration shows good bioavailability (>50%) with Cmax achieved at 1-2 hours. Plasma half-life is approximately 3-5 hours. The compound shows moderate tissue distribution and low brain penetration. Metabolism is primarily via CYP3A4-mediated oxidation.
|
| Toxicity/Toxicokinetics |
In preclinical studies, BTK inhibitor 10 is well-tolerated at therapeutic doses (up to 30 mg/kg). No significant weight loss, organ toxicity, or hematological abnormalities are reported. At high doses (>100 mg/kg), mild gastrointestinal disturbances may occur. No genotoxicity data are available.
|
| References | |
| Additional Infomation |
BTK inhibitor 10 is a research compound, not FDA-approved. It serves as a tool for studying BTK biology and evaluating BTK-targeted therapies for autoimmune diseases such as rheumatoid arthritis. The compound's covalent binding mechanism provides sustained target inhibition, making it valuable for studying irreversible BTK inhibition.
|
| Molecular Formula |
C25H23N5O3
|
|---|---|
| Molecular Weight |
441.481825113297
|
| Exact Mass |
441.18
|
| CAS # |
2241732-30-7
|
| PubChem CID |
134827871
|
| Appearance |
Off-white to light yellow solid powder
|
| LogP |
3.7
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
33
|
| Complexity |
664
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O1CCN(C2C=CC(=CC=2)C2=CC3=C(N=CN=C3N2)OC2C=CC=C(C=2)NC(C=C)=O)CC1
|
| InChi Key |
KLSYFSMLPFKXDQ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C25H23N5O3/c1-2-23(31)28-18-4-3-5-20(14-18)33-25-21-15-22(29-24(21)26-16-27-25)17-6-8-19(9-7-17)30-10-12-32-13-11-30/h2-9,14-16H,1,10-13H2,(H,28,31)(H,26,27,29)
|
| Chemical Name |
N-[3-[[6-(4-morpholin-4-ylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenyl]prop-2-enamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~113.26 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.66 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2651 mL | 11.3255 mL | 22.6511 mL | |
| 5 mM | 0.4530 mL | 2.2651 mL | 4.5302 mL | |
| 10 mM | 0.2265 mL | 1.1326 mL | 2.2651 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
